PAS-004 advances toward Phase 2 as Pasithea seeks new treatment approach for cutaneous neurofibromas
Pasithea Therapeutics secures FDA clearance for PAS-004 Phase 2 testing in NF1 skin tumors. Explore the treatment potential and trial plans.
Pharma & Biotech